Estimating the Willingness to Pay for a Quality-adjusted Life Year in Thailand: Does the Context of Health Gain Matter?

Overview

Journal Clinicoecon Outcomes Res

Publisher Dove Medical Press

Specialty Health Services

Date 2013 Jan 25

PMID 23345984

Citations 42

Authors

Montarat Thavorncharoensap

Yot Teerawattananon

Sirin Natanant

Wantanee Kulpeng

Jomkwan Yothasamut

Pitsaphun Werayingyong

Affiliations

Soon will be listed here.

Abstract

Background: This study aims to elicit the value of the willingness to pay (WTP) for a quality-adjusted life year (QALY) and to examine the factors associated with the WTP for a QALY (WTP/QALY) value under the Thai health care setting.

Methods: A community-based survey was conducted among 1191 randomly selected respondents. Each respondent was interviewed face-to-face to elicit his/her health state preference in each of three pairs of health conditions: (1) unilateral and bilateral blindness, (2) paraplegia and quadriplegia, and (3) mild and moderate allergies. A visual analog scale (VAS) and time trade off (TTO) were used as the eliciting methods. Subsequently, the respondents were asked about their WTP for the treatment and prevention of each pair of health conditions by using a bidding-game technique.

Results: With regards to treatment, the mean WTP for a QALY value (WTP/QALY(treatment)) estimated by the TTO method ranged from 59,000 to 285,000 baht (16.49 baht = US$1 purchasing power parity [PPP]). In contrast, the mean WTP for a QALY value in terms of prevention (WTP/QALY(prevention)) was significantly lower, ranging from 26,000 to 137,000 baht. Gender, household income, and hypothetical scenarios were also significant factors associated with the WTP/QALY values.

Conclusion: The WTP/QALY values elicited in this study were approximately 0.4 to 2 times Thailand's 2008 GDP per capita. These values were in line with previous studies conducted in several different settings. This study's findings clearly support the opinion that a single ceiling threshold should not be used for the resource allocation of all types of interventions.

Citing Articles

Economic evaluation of tenofovir disoproxil fumarate prophylaxis to prevent mother-to-child transmission of Hepatitis B virus infection: evidence from a lower-middle income country.

Nguyen H, Chaikledkaew U, Hoang M, Tran V, Thavorncharoensap M, Praditsitthikorn N BMC Health Serv Res. 2024; 24(1):1658.

PMID: 39732705 PMC: 11681667. DOI: 10.1186/s12913-024-12152-z.

The Costs and Cost-Effectiveness of a Two-Dose Oral Cholera Vaccination Campaign: A Case Study in a Refugee Camp Setting in Thailand.

Wallace A, Date K, Pallas S, Wongjindanon N, Phares C, Abimbola T Vaccines (Basel). 2024; 12(11).

PMID: 39591138 PMC: 11598253. DOI: 10.3390/vaccines12111235.

Projected Cost Savings With Optimal Medication Adherence in Patients With Cardiovascular Disease Requiring Lipid-Lowering Therapy: A Multinational Economic Evaluation Study.

Cho J, Wilson F, Chaikledkaew U, Chen Y, Phrommintikul A, Diaz-Aguilera M J Am Heart Assoc. 2024; 13(22):e037792.

PMID: 39548005 PMC: 11681399. DOI: 10.1161/JAHA.124.037792.

Economic evaluation of diagnosis and treatment for latent tuberculosis infection among contacts of pulmonary tuberculosis patients in Thailand.

Yoopetch P, Wu O, Jittikoon J, Thavorncharoensap M, Youngkong S, Praditsitthikorn N Sci Rep. 2024; 14(1):17693.

PMID: 39085338 PMC: 11291668. DOI: 10.1038/s41598-024-68452-1.

Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges.

Espinosa O, Rodriguez-Lesmes P, Romano G, Orozco E, Basto S, Avila D Appl Health Econ Health Policy. 2024; 22(6):797-804.

PMID: 38995492 PMC: 11470905. DOI: 10.1007/s40258-024-00900-5.

References

Weinstein M, Torrance G, McGuire A . QALYs: the basics. Value Health. 2009; 12 Suppl 1:S5-9. DOI: 10.1111/j.1524-4733.2009.00515.x. View

Freemantle N . Valuing the effects of sildenafil in erectile dysfunction. Strong assumptions are required to generate a QALY value. BMJ. 2000; 320(7243):1156-7. PMC: 1127569. DOI: 10.1136/bmj.320.7243.1156. View

OBrien B, Gertsen K, Willan A, Faulkner L . Is there a kink in consumers' threshold value for cost-effectiveness in health care?. Health Econ. 2002; 11(2):175-80. DOI: 10.1002/hec.655. View

Permsuwan U, Guntawongwan K, Buddhawongsa P . Handling time in economic evaluation studies. J Med Assoc Thai. 2009; 91 Suppl 2:S53-8. View

Bobinac A, van Exel N, Rutten F, Brouwer W . Willingness to pay for a quality-adjusted life-year: the individual perspective. Value Health. 2010; 13(8):1046-55. DOI: 10.1111/j.1524-4733.2010.00781.x. View

Smith R, Richardson J . Can we estimate the 'social' value of a QALY? Four core issues to resolve. Health Policy. 2005; 74(1):77-84. DOI: 10.1016/j.healthpol.2004.12.009. View

Ubel P, Hirth R, Chernew M, Fendrick A . What is the price of life and why doesn't it increase at the rate of inflation?. Arch Intern Med. 2003; 163(14):1637-41. DOI: 10.1001/archinte.163.14.1637. View

Shiroiwa T, Sung Y, Fukuda T, Lang H, Bae S, Tsutani K . International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?. Health Econ. 2009; 19(4):422-37. DOI: 10.1002/hec.1481. View

Rheingans R, Haddix A, Messonnier M, Meltzer M, Mayard G, Addiss D . Willingness to pay for prevention and treatment of lymphatic filariasis in Leogane, Haiti. Filaria J. 2004; 3(1):2. PMC: 356926. DOI: 10.1186/1475-2883-3-2. View

10.

Hirth R, Chernew M, Miller E, Fendrick A, Weissert W . Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000; 20(3):332-42. DOI: 10.1177/0272989X0002000310. View

11.

Grosse S . Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2010; 8(2):165-78. DOI: 10.1586/14737167.8.2.165. View

12.

Johannesson M, Jonsson B, Karlsson G . Outcome measurement in economic evaluation. Health Econ. 1996; 5(4):279-96. DOI: 10.1002/(SICI)1099-1050(199607)5:4<279::AID-HEC218>3.0.CO;2-J. View

13.

Lieu T, Ray G, Ortega-Sanchez I, Kleinman K, Rusinak D, Prosser L . Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster. Pharmacoeconomics. 2009; 27(12):1005-16. DOI: 10.2165/11314000-000000000-00000. View

14.

Mason H, Baker R, Donaldson C . Willingness to pay for a QALY: past, present and future. Expert Rev Pharmacoecon Outcomes Res. 2010; 8(6):575-82. DOI: 10.1586/14737167.8.6.575. View

15.

Brouwer W, van Exel J, Baker R, Donaldson C . The new myth: the social value of the QALY. Pharmacoeconomics. 2007; 26(1):1-4. DOI: 10.2165/00019053-200826010-00001. View

16.

Cunningham S, Hunt N . Relationship between utility values and willingness to pay in patients undergoing orthognathic treatment. Community Dent Health. 2001; 17(2):92-6. View

17.

Nord E, Daniels N, Kamlet M . QALYs: some challenges. Value Health. 2009; 12 Suppl 1:S10-5. DOI: 10.1111/j.1524-4733.2009.00516.x. View

18.

Zhao F, Yue M, Yang H, Wang T, Wu J, Li S . Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis. Med Care. 2011; 49(3):267-72. DOI: 10.1097/MLR.0b013e31820192cd. View

19.

Lee G, Salomon J, Gay C, Hammitt J . Preferences for health outcomes associated with Group A Streptococcal disease and vaccination. Health Qual Life Outcomes. 2010; 8:28. PMC: 2848145. DOI: 10.1186/1477-7525-8-28. View

20.

Jirawattanapisal T, Kingkaew P, Lee T, Yang M . Evidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan. Value Health. 2010; 12 Suppl 3:S4-11. DOI: 10.1111/j.1524-4733.2009.00620.x. View